Detalhe da pesquisa
1.
The CAPACITI Decision-Support Tool for National Immunization Programs.
Value Health;
24(8): 1150-1157, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34372981
2.
Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap.
Sex Health;
16(5): 426-432, 2019 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31476278
3.
Critical Needs in Advancing Shigella Vaccines for Global Health.
J Infect Dis;
225(9): 1500-1503, 2022 05 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34558631
4.
Facilitating the development of urgently required combination vaccines.
Lancet Glob Health;
12(6): e1059-e1067, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38636529
5.
The role of vaccines in reducing antimicrobial resistance: A review of potential impact of vaccines on AMR and insights across 16 vaccines and pathogens.
Vaccine;
2024 Jun 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38876836
6.
Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert convening.
Vaccine;
41(16): 2634-2644, 2023 04 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36932030
7.
Vaccine value profile for Shigella.
Vaccine;
41 Suppl 2: S76-S94, 2023 11 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37827969
8.
Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries.
Lancet Glob Health;
11(11): e1819-e1826, 2023 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37858591
9.
What Drives the Value of a Shigella Vaccine?
Vaccines (Basel);
10(2)2022 Feb 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35214740
10.
Pivotal Shigella Vaccine Efficacy Trials-Study Design Considerations from a Shigella Vaccine Trial Design Working Group.
Vaccines (Basel);
10(4)2022 Mar 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35455238
11.
Global diarrhoea-associated mortality estimates and models in children: Recommendations for dataset and study selection.
Vaccine;
39(32): 4391-4398, 2021 07 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34134905
12.
World Health Organization Expert Working Group: Recommendations for assessing morbidity associated with enteric pathogens.
Vaccine;
39(52): 7521-7525, 2021 12 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34838322
13.
How can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings? A total systems effectiveness (TSE) approach to decision-making.
Vaccine X;
6: 100078, 2020 Dec 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33196036
14.
Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019.
Vaccine;
38(28): 4362-4373, 2020 06 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32359875
15.
Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy.
Vaccine;
37(50): 7372-7380, 2019 11 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29031690
16.
Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016.
Vaccine;
37(50): 7315-7327, 2019 11 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28262332
17.
Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016.
Vaccine;
37(50): 7355-7362, 2019 11 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28302410
18.
WHO consultation on ETEC and Shigella burden of disease, Geneva, 6-7th April 2017: Meeting report.
Vaccine;
37(50): 7381-7390, 2019 11 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29352598
19.
Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017.
Vaccine;
37(50): 7408-7418, 2019 11 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29224963
20.
How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?
Vaccine;
37(34): 4778-4783, 2019 08 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31358238